

Table SI. Overview of included studies

Author, Year (ref.)	Publication type	Country	Study design	Recruitment setting	Primary objective (s)	Instru-ment (s)	Patients, N <sup>b</sup>	Boys/girls ratio	Age range, years (mean)	Mean (SD) PASI disease severity <sup>d</sup>	Mean (SD) HRQOL
Balci et al., 2007 (63)	Published article	Turkey	Observational study	Dermatology clinic	To assess the validity and reliability of the Turkish version of the CDLQI	CDLQI	6	NA	5-16 (NA)	NA	7.76 (4.08)
Beattie & Lewis-Jones, 2006 (64)	Published article	UK	Observational study	Dermatology clinic	a) To cross-validate a new generic HRQOL proxy instrument (Children's Life Quality Index, CLQI) b) To compare skin disease with other common chronic childhood diseases	CDLQI	29	11/18	5-16 (10.2)	NA	9.17 (7.83)
Bigic et al., 2010a (33)	Published article <sup>a</sup>	Turkey	Observational study (child group)	Dermatology clinic	To examine the symptoms of depression and anxiety and HRQOL in children and adolescents with psoriasis vs. healthy controls	PedsQL	22		8-12 (10.1)	6.4 (7.0)	72.83 (13.20)
Bigic et al., 2010b (33)	Published article <sup>a</sup>	Turkey	Observational study (adolescent group)	Dermatology clinic	To examine the symptoms of depression and anxiety and HRQOL in children and adolescents with psoriasis vs. healthy controls	PedsQL	26	17/31 (combined sample)	13-18 (15.3)	9.8 (10.5)	75.33 (14.93)
Chang et al., 2010 (67)	Conference abstract and poster	Malaysia	Observational study	Dermatology clinics (n = 13)	To study the socio-demographic characteristics, clinical manifestation, comorbidities, treatment, outcome, and HRQOL issues of patients with psoriasis	DLQI	180	NA	NA	NA	7.50 (6.52)
de Jager et al., 2011 (61)	Published article (Brief report)	The Netherlands	Observational study	General population database	Pilot study to explore the physical, emotional, and social limitations that children with psoriasis have to cope with	CDLQI	15	4/11	3-17.6 (12.8)	Mostly mild psoriasis	2.90 (2.90)
Gånemo et al., 2011 (50)	Published article <sup>a</sup>	Sweden	Observational study	Dermatology clinics (n = 2)	a) To assess Quality-of-Life in children and parents b) To examine relations between clinical data and QoL	CDLQI	42	17/28	5-16 (12.9)	4.9 (3.2)	5.05 (5.00)
van Geel et al., 2016 (60)	Published article	The Netherlands	Observational study	Dermatology clinic	To compare DLQI and CDLQI scores in patients with psoriasis aged 16-17 years	CDLQI	56	24/32	16-17 (16.6)	NA	CDLQI: 6.61 (5.74) DLQI: 5.41 (5.20)
Khawaja et al., 2015 (48)	Published article <sup>a</sup>	Pakistan	Observational study	Dermatology clinics (n = 3)	To explore the severity of psoriasis, dermatology-related quality of life, and psychiatric health of the patients with reference to sociodemographic, lifestyle, and clinical characteristics	DLQI	8	7/1	13-18 (15.5)	8.0 (10.3)	9.49 (9.17)
Landells et al., 2015 (63)	Published article	Canada and Europe	Intervention study	Dermatology clinics (n = 36)	To evaluate treatment effect in adolescents with moderate-to-severe psoriasis	CDLQI	101	54/65 <sup>c</sup>	12-17 (15.2)	21.1 (8.9)	9.60 (6.50)
Langley et al., 2011a (34)	Published article	USA and Canada	Intervention study (treatment group)	Dermatology clinics (n = 42)	To evaluate efficacy and safety of treatment	CDLQI and PedsQL	CLDQI: 100 PedsQL: 104	55/51	4-17 (12.2)	18.5 (6.7)	CDLQI: 8.90 (6.00) PedsQL: 74.80 (17.80)
Langley et al., 2011b (34)	Published article	USA and Canada	Intervention study (placebo group)	Dermatology clinics (n = 42)	To evaluate efficacy and safety of treatment	CDLQI and PedsQL	CDLQI: 102 PedsQL: 104	53/52	4-17 (11.7)	18.6 (6.8)	CDLQI: 10.00 (6.40) PedsQL: 76.10 (16.90)
Lewis-Jones & Finlay, 1995 (25)	Published article	UK	Observational study	Dermatology clinic	To develop and initially validate the CDLQI instrument	CDLQI	25	7/18	4-16 (10.4)	NA	5.40 (5.00)
Manzoni et al., 2012 (65)	Published article	Brazil	Observational study	Dermatology clinics (n = 3)	a) To compare quality of life across paediatric patients with atopic dermatitis, psoriasis and vitiligo b) To correlate the findings with clinical findings	CDLQI	25	NA	5-16 (NA)	BSA total: mdn: 6 (range: 2-37) BSA exposed, mdn: 4 (range: 1-6.5)	7.90 (3.20)
Matusiewicz et al., 2013 (66)	Published article	Germany	Observational study	Online survey	To characterize the health-care situation and quality of life in children and adolescents with psoriasis	CDLQI	84	27/57	5-16 (NA)	NA	7.60 (3.50)

Table SI. Contd.

Matterne & Apfelbacher, 2016 (46)	Published article	Germany	Observational study	Randomly selected from local population registries across the county	To describe HRQOL in paediatric psoriasis compared with psoriasis-free children and adolescents	KINDL-R	108	NA	11-17 (NA)	NA	69.85
Oostveen et al., 2012 (49)	Published article	The Netherlands	Observational study	Dermatology clinic	To assess the CDLQI in a cohort of patients with juvenile psoriasis and to evaluate the influence of treatments in daily clinical practice on CDLQI	CDLQI	125	46/79	3-17 (10.7)	7.0 (5.8)	6.50 (5.00)
Papp et al., 2014 (35)	Conference abstract	Multi-site international study	Intervention study	Dermatology clinics (NA)	To report baseline characteristics of an ongoing intervention study	CDLQI and PedsQL	114	49/65	4-18 (13.0)	18.3 (8.8)	CDLQI: 11.30 (6.79) PedsQL: 73.10 (17.44)
Smidt et al., 2010 (47)	Published article	USA	Observational study	Dermatology clinic	To develop and validate a quality-of-life instrument (Skindex-Teen) for adolescents with skin-disease	Skindex-Teen	11	NA	12-17 (NA)	NA	21.20 (10.30)

<sup>a</sup>Additional unpublished data provided on request. <sup>b</sup>Total N for patients with psoriasis enrolled in HRQOL aim. <sup>c</sup>No separate data on patients enrolled in HRQOL aim available, the ratio reported relates to total sample of paediatric patients (n=119). <sup>d</sup>Measured by Psoriasis Area and Severity Index (PASI) unless otherwise specified. CDLQI: Children's Dermatology Quality of Life Index; DLQI: Dermatology Quality of Life Index; PedsQL: The Pediatric Quality of Life Inventory; PASI: Psoriasis Area Severity Index; BSA: body surface area; NA: not available; Mdn: median.